CEFOXITIN SODIUM

Search structure


Trade Names:	CEFOXITIN CEFOXITIN AND DEXTROSE IN DUPLEX CONTAINER CEFOXITIN IN PLASTIC CONTAINER MEFOXIN MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER MEFOXIN IN PLASTIC CONTAINER MEFOXIN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Synonyms:	Cefoxitin Cefoxitin sodium Cefoxitin sodium salt Mefoxin
Status:	Approved (1978)
Entry Type:	Small molecule
Molecule Category:	Salt
UNII:	Q68050H03T
Parent Compound:	CEFOXITIN

Structure


InChI Key	GNWUOVJNSFPWDD-XMZRARIVSA-M
Smile	CO[C@@]1(NC(=O)Cc2cccs2)C(=O)N2C(C(=O)[O-])=C(COC(N)=O)CS[C@@H]21.[Na+]
InChI	InChI=1S/C16H17N3O7S2.Na/c1-25-16(18-10(20)5-9-3-2-4-27-9)13(23)19-11(12(21)22)8(6-26-15(17)24)7-28-14(16)19;/h2-4,14H,5-7H2,1H3,(H2,17,24)(H,18,20)(H,21,22);/q;+1/p-1/t14-,16+;/m1./s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C16H16N3NaO7S2
Molecular Weight	449.44
AlogP	0.1
Hydrogen Bond Acceptor	8.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	7.0
Polar Surface Area	148.26
Molecular species	ACID
Aromatic Rings	1.0
Heavy Atoms	28.0

Pharmacology

Action	Mechanism of Action	Reference
INHIBITOR	Bacterial penicillin-binding protein inhibitor	PubMed PubMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	69

Indications

Mesh Heading	Maximum Phase	Mesh ID	Reference

Related Entries

Scaffolds

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Target Level :

Level 3

Level 4

Level 5

Level 6

Extend network:

Indication

Mechanism of Action

Primary Target

Target Level

Parent

Adverse Reactions

SOC By Demographic Distribution

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	14.43
Skin and subcutaneous tissue disorders	13.4
Immune system disorders	12.71
Blood and lymphatic system disorders	8.25
Gastrointestinal disorders	7.9
Vascular disorders	6.87
Infections and infestations	5.84
Injury, poisoning and procedural complications	5.84
Musculoskeletal and connective tissue disorders	5.15
Cardiac disorders	3.44
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	3.09
Ear and labyrinth disorders	2.75
Respiratory, thoracic and mediastinal disorders	2.75
Investigations	2.06

Cross References

Resources	Reference
ChEBI	3501
ChEMBL	CHEMBL1200530
EPA CompTox	DTXSID8048995
FDA SRS	Q68050H03T
KEGG	C08106
PubChem	23667300
SureChEMBL	SCHEMBL41178

CONTENTS